

In re Appln. of Flack et al.
Serial No. 08/379,872

1 cont
effective amount of said compound results in a blood
concentration of said compound of 200-1000 ng/dl.

2
13. (Twice Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, [or] a pharmaceutically acceptable salt of gossypol, or a combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of [a] at least one compound selected from the group consisting of gossypol[, or] and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein administration of said anti-cancer effective amount of said compound results in a blood concentration of said compound of 200-1000 ng/dl.

Please add the following new claims:

3
~~416~~. The method of claim 1, wherein the blood concentration of said compound is 400-1000 ng/dl.

~~5~~
~~17~~. The method of claim ~~16~~⁴, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.

~~6~~
~~18~~. The method of claim ~~17~~⁵, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.

In re Appln. of Flack et al.
Serial No. 08/379,872

⁵
~~7~~¹⁰. The method of claim ~~17~~⁵, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.

¹¹
~~20~~¹¹. The method of claim ~~13~~⁸, wherein the blood concentration of said compound is 400-1000 ng/dl.

¹²
~~21~~¹². The method of claim ~~13~~⁸, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

¹³
~~22~~¹³. The method of claim ~~13~~⁸, wherein said compound is administered orally at a dose of 20-100 mg/d.

¹⁴
~~23~~¹⁴. The method of claim ~~13~~⁸, wherein said compound is administered rectally at a dose of 40-140 mg/d.

REMARKS

The Present Invention

The present invention is directed to a method of treating a cancer in a human wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, gossypolone, a pharmaceutically acceptable salt of gossypolone, or any combination thereof. The method comprises administering to the human an anti-cancer effective amount of one or more of the aforementioned compounds in a pharmaceutically acceptable carrier.